Looking to retain its runner-up position in HIV, Merck scores two new approvals for HIV therapies
Merck $MRK scored two new drug OKs in HIV, offering a pair of antiretroviral therapies to patients. But they’re unlikely to offer much of a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
